Flux assays, particularly nonradiolabeled rubidium-based assays, offer a high-throughput, automated alternative to patch clamping for ion channel drug discovery.
Answers are grounded in this paper and cite their sources.
May accelerate high-throughput ion channel screening; leaves open prospective validation for cardiovascular drug development.
Ion channels have been identified as therapeutic targets in various disorders, such as cardiovascular disease, neurological disease, and cystic fibrosis. Flux assays to detect functional ionic flux through ion channels are becoming increasingly popular as tools for screening compounds. In an optimized flux assay, modulation of ion channel activity may produce readily detectable changes in radiolabeled or nonradiolabeled ionic flux. Technologies based on flux assays are currently available in a fully automated high throughput format for efficient screening. This application offers sensitive, precise, and reproducible measurements giving accurate drug rank orders matching those of patch clamp data. Conveniently, the flux assay is amenable to adaptation for different ion channels, such as potassium, sodium, calcium, and chloride channels, by using suitable tracer ions. The nonradiolabeled rubidium-based flux assay coupled with the ion channel reader (ICR) technology has become very successful in ion channel activity analysis and is emerging as a popular technique in modern drug discovery.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: